Genprex, Inc. GNPX 深 滬
已收盤 08-29 16:00:00 美东时间
0.164
-0.011
-6.12%
華盛通- 最 高0.1799
- 今 開0.1799
- 成交量 274.10万股
- 最 低 0.1489
- 昨 收 0.1747
- 總市值 548.86万
- 52周最高 3.97
- 市盈率 靜 --
- 換手率 8.19%
- 52周最低 0.14
- 委 比 50.00%
- 總股本 3346.68万
- 歷史最高 778.00
- 量 比 0.12
- 振 幅 17.74%
- 歷史最低 0.14
- 每 手 1
- 風險率 3.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers ModivCare (NASDAQ:MODV) stock increased by 69.6% to $0.95 during Frida...
08-22 20:08
Genprex Secures Patent Allowances for Gene Therapy
Genprex ( ($GNPX) ) just unveiled an update. On August 18, 2025, Genprex announ...
08-18 21:47
Genprex Q2 EPS $(0.17) Beats $(0.42) Estimate
Genprex (NASDAQ:GNPX) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.42) by 59.52 percent. This is a 94.33 percent increase over losses of $(3.00) per share from the same
08-15 05:21
Genprex Issues Stockholder Letter and Provides 2025 Corporate Update
Company Achieves Multiple Clinical Development Milestones in 2025 Patient Treatment Continues in Two Lung Cancer Clinical Trials AUSTIN, Texas, Aug. 4, 2025 /PRNewswire/ -- Genprex, Inc. ("G...
08-04 20:30
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Pluri (NASDAQ:PLUR) shares moved upwards by 24.0% to $5.99 during Tues...
07-02 05:05
Genprex Announces That Its Research Collaborators Presented Positive Preclinical Data And Research From Studies Of Gpx-002 At The 2025 American Diabetes Association 85th Scientific Session In Chicago
Novel Diabetes Gene Therapy Shows Potential for Re-Dosing Using Non-Viral Delivery SystemGenprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing
06-23 21:04
Genprex Enters $12.5M Stock Purchase Agreement
Genprex ( ($GNPX) ) has issued an update. On June 11, 2025, Genprex entered int...
06-12 05:51
Genprex to Participate at BIO 2025 International Convention
AUSTIN, Texas, June 3, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for...
06-03 19:00
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
<p>Gain Therapeutics, Inc. announced an oral presentation at the GBA1 Meeting 2025 in Montreal, Canada, set for June 5-7. The presentation, scheduled for June 5 at 11:20 p.m. EST, will be delivered by Jonas Hannestad, M.D., Ph.D., the Company's Chief Medical Officer. Gain is focused on developing next-generation allosteric therapies, with its lead candidate, GT-02287, currently in a Phase 1b trial for Parkinson’s disease, and showing potential fo...
05-29 12:45
